PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

NCT02867332 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No funding

Conditions

Metastatic Renal Cell Carcinoma

Interventions

BIOLOGICAL: PD-1 Knockout T Cells
DRUG: Cyclophosphamide
DRUG: IL-2

Sponsor

Peking University